Shigellosis remains a common gastrointestinal disease in developing and industrialized countries. It occurs mostly in children \<5 years of age; *Shigella sonnei* is the most frequently isolated species ([@R1]). Ampicillin and trimethoprim-sulfamethoxazole alleviate the dysenteric syndrome of shigellosis and reduce the infectious period. However, current resistance patterns limit the use of these drugs ([@R2]). Although fluoroquinolones are an effective alternative for adults, they are not approved for shigellosis treatment in children \<18 years of age because of their potential toxicity ([@R2],[@R3]). Azithromycin, a macrolide, represents an attractive treatment option for several reasons. It has in vitro activity against most *Shigella* spp. isolates ([@R4]), can be given once a day, and attains high intracellular concentrations ([@R5]). Despite MICs from 2 to 8 mg/L for *Shigella* spp., sufficient concentrations of azithromycin in the colon may inhibit *Shigella* spp. growth ([@R6]). Azithromycin is recommended by the American Academy of Pediatrics for treatment of shigellosis in children, by the World Health Organization as a second-line treatment in adults, and, since June 2004, by the Agence Française de Sécurité Sanitaire des Produits de Santé ([@R2],[@R7]; [www.agmed.sante.gouv.fr/htm/10/filcoprs/mp040601.pdf](http://www.agmed.sante.gouv.fr/htm/10/filcoprs/mp040601.pdf)). In 1996, 2002, 2003, and 2007, outbreaks of shigellosis caused by *S. sonnei* resistant to ampicillin and trimethoprim-sulfamethoxazole occurred in children in northern Paris. The outbreaks occurred in religious schools, similar to cyclic outbreaks in US Jewish schools related to secondary transmission ([@R8],[@R9]).We report an outbreak of shigellosis in and around Paris, France, in which azithromycin failure was related to emergence of plasmid-mediated resistance to macrolides.

The Study
=========

On January 24, 2007, *S. sonnei* strain UCN59 was isolated from a 4-year-old girl admitted to Robert Debré Hospital, Paris, for bloody diarrhea and fever. The strain was resistant to ampicillin, trimethoprim, sulfonamides, and cotrimoxazole but susceptible to quinolones, third-generation cephalosporins, and doxycycline according to the disk-diffusion technique. MICs of macrolides were markedly increased for *S. sonnei* UCN59 compared with those for a susceptible control *S. sonnei* UCN62 ([Table](#T1){ref-type="table"}). From January to April 23, 2007, a total of 50 cases of laboratory-confirmed shigellosis were identified. Isolates included, in addition to UCN59, 31 *S. sonnei* that had an azithromycin MIC [\>]{.ul}64 mg/L from 31 children \<15 years of age, who had each been prescribed azithromycin for diarrhea. All patients lived in the Paris area and attended 8 religious schools.

###### Macrolide susceptibility of outbreak and control *Shigella* isolates and *Escherichia coli* constructs

  Strain                                MIC, mg/L                 
  ------------------------------------- ----------- ------- ----- -----
  *Shigella sonnei* UCN 62              64          32      2     8
  *S. sonnei* UCN 59                    1,024       1,024   64    64
  *Escherichia coli* K12 AG100A         2           2       2     1
  *E. coli* K12 AG100A/pUV21            512         512     8     32
  *E. coli* K12 AG100A/pUC18Ω*mph*(A)   \>1,024     512     128   512

Typing by pulsed-field gel electrophoresis (PFGE) and repetitive sequence--based PCR (rep-PCR) by using the automated DiversiLab system (bioMérieux, La-Balme-les-Grottes, France) ([@R10]) was performed on the 32 azithromycin-resistant and on 11 azithromycin-susceptible (MIC \<16 mg/L) sporadic or outbreak isolates obtained during 1996--2007 in the Paris area. Five different PFGE patterns were obtained by using the enzyme *Bln*I. All the 2007 outbreak isolates, including the 32 azithromycin-resistant isolates and 2 azithromycin-susceptible isolates, were clustered into a single profile, profile 1 ([Figure 1](#F1){ref-type="fig"}). The presence of azithromycin-susceptible isolates with profile 1 was detected among the 1996 and 2002--2006 outbreak isolates (data not shown), showing the persistence of this clonal type over 10 years in this area of Paris. Other isolates displayed PFGE types 2 to 5. Low diversity of PFGE profiles was consistent with isolation of strains in the same area and for most of them from the same community. Four different patterns with \<97% similarity were distinguished by rep-PCR ([Figure 2](#F2){ref-type="fig"}). Again, all the 2007 azithromycin-resistant isolates were clustered; however, they could be distinguished from the 2007 azithromycin-susceptible isolates. In contrast to PFGE findings, rep-PCR showed that isolates representative of the 1996, 2002, and 2003 outbreaks were genetically related.

![Pulsed-field gel electrophoresis--generated dendrogram for 43 *Shigella sonnei* isolates obtained from sporadic or outbreak cases during 1996--2007 in the Paris area. Profile 1) representative isolates from the 2007 outbreak, including 32 isolates with azithromycin MIC \>256 mg/L by Etest and 2 isolates with azithromycin MIC \<16 mg/L. Profile 2) 6 representative isolates from sporadic cases (2003--2006) with azithromycin MIC \<16 mg/L. Profile 3) representative isolate Shi 03-3580 from 2003 outbreak with azithromycin MIC \<16 mg/L by Etest. Profile 4) representative isolate Shi 02-9633 from 2002 outbreak with azithromycin MIC \<16 mg/L by Etest. Profile 5) representative isolate Shi 96 1420 from 1996 outbreak with azithromycin MIC \<16 mg/L by Etest.](08-0147-F1){#F1}

![Repetitive sequence--based, PCR--generated dendrogram for 43 *Shigella sonnei* isolates obtained from sporadic or outbreak cases during 1996--2007 in the Paris area. Isolates with [\>]{.ul}97% similarity were considered to be closely genetically related. Profile 1) representative of the 32 isolates of the 2007outbreak with azithromycin (MIC \>256 mg/L by Etest) . Profile 2) 1 of 6 isolates from sporadic cases (2003--2006) with azithromycin MIC \<16 mg/L. Profile 3) representative isolate Shi 03-3580 from 2003 outbreak with azithromycin MIC \<16 mg/L by Etest. Profile 4) representative isolate Shi 02-9633 from 2002 outbreak with azithromycin MIC \<16 mg/L by Etest. Profile 5) representative isolate Shi 96 1420 from 1996 outbreak with azithromycin MIC \<16 mg/L by Etest. Profile 6) isolate from 2007 with azithromycin MIC \<16 mg/L by Etest; another AZM S 2007 isolate had an identical profile. AZM, azithromycin; R, resistant; S, sensitive; Rep, repetitive sequence-based PCR.](08-0147-F2){#F2}

The *mph*(A) gene, which encodes a macrolide 2′-phosphotransferase that inactivates macrolide antimicrobial drugs, was amplified from *S. sonnei* UCN59 DNA by PCR ([@R11]). PCR was negative for the *erm*(A), *erm*(TR), *erm*(B), *erm*(C), and *erm*(X) methylase genes; the *ere*(A), *ere*(B) genes encoding esterases; the *mph*(B) gene encoding a phosphotransferase; and the efflux genes *mef*(A) and *msr*(A). Sequence of the genes that encode ribosomal structures composing the target of macrolides, *rrl*, *rplD,* and *rplV* genes in *S. sonnei* UCN59, did not display any mutation in the critical bases of resistance to macrolides.

The genes conferring resistance to ampicillin and erythromycin were transferred en bloc by conjugation from *S. sonnei* UCN59 to a macrolide-susceptible mutant *Escherichia coli* AG100A at a frequency of ≈10^--3^ per donor cell-forming unit after the mating period. A single plasmid was extracted from a transconjugant *E. coli* AG100A/pUV21. After restriction analysis, its size was estimated at ≈90 kb. PCR experiments showed that this plasmid belonged to incompatibility group I ([@R12]). MICs of macrolides for *E. coli* AG100A/pUV21 confirmed that this plasmid conferred cross-resistance to macrolides ([Table](#T1){ref-type="table"}).

*Eco*RI-restricted fragments of plasmid pUV21 were transferred to a nylon membrane and hybridized to an *mph*(A) probe. The *mph*(A) gene was borne by an ≈20-kb *Eco*RI fragment, confirming that resistance to azithromycin was plasmid mediated.

After plasmid digestion with *Pst*I enzyme, a DNA fragment that conferred resistance to erythromycin was cloned in plasmid pUC18 and introduced by transformation into *E.* *coli* AG100A to generate *E. coli* K12 AG100A/pUC18Ω*mph*(A). Sequence of the inserted DNA was determined. The fragment contained 4 open reading frames (ORFs) in the same orientation: *mph*(A), *mrx* that putatively encodes a membrane protein, *mphR*(A) that regulates the expression of *mph*(A), and an ORF of unknown function. This series of ORFs was flanked by a copy of IS*26* at the 5′ end and a copy of IS*6100* at the 3′ end. BLAST analysis ([www.ncbi.nlm.nih.gov/blast/Blast.cgi](http://www.ncbi.nlm.nih.gov/blast/Blast.cgi)) showed that the nucleotide sequence was nearly identical to that of fragments of plasmid pU302L from *Salmonella* *enterica* serotype Typhimurium (C.Y. Chen et al., unpub. data, GenBank accession no. NC_006816), of *Shigella flexneri* transposon TnSF1 (J.H. Chen and J.Y. Chen, unpub. data, GenBank accession no. AF188331), and of plasmids pRSB101 and pSRB107 ([@R13],[@R14]).

Conclusions
===========

Few data are available on azithromycin resistance in *Shigella* spp. A recent report from Bangladesh mentioned that 16% of *Shigella* isolates were resistant to azithromycin and that 62% had intermediate resistance according to the Clinical Laboratory Standards Institute breakpoints recommended for streptococci ([\>]{.ul}1 mg/L, resistant; \<0.25 mg/L, susceptible) ([@R15]). However, the MIC~90~ (MIC at which 90% are susceptible) of 8 mg/L displayed by the microorganisms was within the normal range of MICs for this microorganism; no isolate had an azithromycin MIC \>24 mg/L, which suggests that none had acquired resistance to azithromycin. Surveillance for resistance to azithromycin in *Shigella* spp. requires specific breakpoints for this species ([@R3]).

The *mph*(A) gene has been detected in the sequence of transposon TnSF1 isolated from *S. flexneri* (J.H. Chen and J.Y. Chen JY, unpub. data, GenBank accession no. AF188331). The *mph*(A) gene was first reported in an *E. coli* isolate from Japan ([@R10]). Since then, the gene has been found in *Aeromonas hydrophila*, *Pseudomonas* spp., *Stenotrophomonas* spp., and a variety of enterobacteria (listed at <http://faculty.washington.edu/marilynr/ermweb4.pdf>).

Azithromycin was used to treat shigellosis in France only after the release of the French recommendations in 2004. Subsequent rapid emergence of azithromycin-resistant isolates may be a limitation for the use of macrolides in shigellosis. Because use of azithromycin is proposed for treatment of shigellosis, susceptibility of the isolates to azithromycin should be routinely tested.
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